Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ovid Therapeutics Inc.
Headquarters: New York, NY, United States of America
Website: https://ovidrx.com/
Year Founded: 2014
Status: Public
Industry Sector: HealthTechnology
CEO: Jeremy Max Levin, MD, PhD
Number Of Employees: 23
Enterprise Value: $27,884,393
PE Ratio: -0.76
Exchange/Ticker 1: NASDAQ:OVID
Exchange/Ticker 2: N/A
Latest Market Cap: $21,422,000
BioCentury | Mar 4, 2025
Management Tracks
Head of R&D Robert Lenz to leave Neumora
Plus: Jeffrey Sevigny named CMO of Rapport, and updates from Garuda, Metis, Ovid and more
BioCentury | Dec 10, 2024
Politics, Policy & Law
Biosecure setback & Novartis’ $1B PTC Deal: a BioCentury podcast
Plus: KCC2 activation nears inflection point
BioCentury | Dec 6, 2024
Product Development
KCC2 activation nears inflection point
Ovid, Axonis and others are poised to take therapies against the long undruggable KCC2 to the clinic for neurological disorders
BioCentury | Nov 6, 2024
Editor's Commentary
Myths and misperceptions — industry’s stumbling blocks
What are biotechs, pharmas and academics getting wrong about each other?
BioCentury | Sep 12, 2024
Management Tracks
Ovid promotes Alexander to COO
Plus: Tyra hires Warner as CMO and updates from Senisca, Closed Loop, NanoSyrinx and more
BioCentury | Aug 15, 2024
Finance
No sleep for the biotech bear: Restructurings abound in August
At least 20 companies have trimmed pipelines, cut staff or otherwise re-jiggered strategies in past two weeks to extend runway
BioCentury | Aug 13, 2024
Management Tracks
Lyell, Juno veteran Albertson becomes Caribou’s CMO
Plus: 10x names CCO, CFO and updates from Ovid, Cerevance, Fore, Atavistik, Velia, SpyBiotech, Telomir, Sernova and Holoclara
BioCentury | Jul 23, 2024
Product Development
Clinical Report: Ionis’ therapy for Angelman syndrome heading for Phase III
Plus: Data from Innovent, Agenus, Merck, Bayer and Orion
BioCentury | Jul 19, 2024
Management Tracks
Remembering Lisa Burns, biotech’s ‘CEO whisperer’
An IR/PR pioneer, Burns connected CEOs, investors and analysts and played host to JPM’s best party
BioCentury | Jul 10, 2024
Management Tracks
Promotions for Flagship’s Afzelius, Biondi come amid $3.6B raise
Plus: EveryONE names CEO and chairman and updates from Lunit, Quell, ImCheck, Aktis, Immunic and Curve
Items per page:
1 - 10 of 126